Immunology

Aging (Aging-US)

Aging-US published this trending research paper in Volume 15, Issue 1, entitled, "The innate immune signaling component FBXC-58 mediates dietary restriction effects on healthy aging in Caenorhabditis elegans" by researchers from the Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun 55365, South Korea; Department of Food Biotechnology, University of Science and Technology, Daejeon-si 34113, South Korea. 

DOI - https://doi.org/10.18632/aging.204477

Corresponding author - Jeong-Hoon Hahm - hahmjh@kfri.re.kr , Jiyun Ahn - jyan@kfri.re.kr 

Abstract

Dietary restriction (DR) is a highly effective and reproducible intervention that prolongs longevity in many organisms. The molecular mechanism of action of DR is tightly connected with the immune system; however, the detailed mechanisms and effective downstream factors of immunity that mediate the beneficial effects of DR on aging remain unknown. Here, to investigate the immune signaling that mediates DR effects, we used Caenorhabditis elegans, which has been widely used in research, to understand the underlying molecular mechanisms of aging and immunity. We found that the F-box gene, fbxc-58, a regulator of the innate immune response, is a novel mediator of DR effects on extending the health span of C. elegans. fbxc-58 is upregulated by DR and is necessary for DR-induced lifespan extension and physical health improvement in C. elegans. Furthermore, through DR, fbxc-58 prevents disintegration of the mitochondrial network in body wall muscle during aging. We found that fbxc-58 is a downstream target of the ZIP-2 and PHA-4 transcription factors, the well-known DR mediator, and fbxc-58 extends longevity in DR through an S6 kinase-dependent pathway. We propose that the novel DR effector, fbxc-58, could provide a new mechanistic understanding of the effects of DR on healthy aging and elucidate the signaling mechanisms that link immunity and DR effects with aging.

Sign up for free Altmetric alerts about this article - 
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204477

Keywords - dietary restriction, aging, innate immunity, F-box protein, Caenorhabditis elegans

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://youtube.com/Aging-US
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

FBXC-58 Mediates Dietary Restriction Effects in Healthy Aging C. Elegans

CloudLIMS

Watch our on-demand COVID-19 webinar to learn how COVID-19 diagnostic laboratories can increase testing throughput, follow compliance with ease, and securely deliver test reports to testees.

On-Demand Webinar: Accelerate COVID-19 Testing and Securely Deliver Test Reports

Agilent Cell Analysis


The Seahorse T Cell Metabolic Profiling persistence assay and fitness assay are designed to streamlines characterization of T cell therapeutic potential. View this video to learn how to interpret these assay results.

Agilent XF T Cell Metabolic Profiling Assay Data Interpretation Guide

Agilex Biolabs

Did you know? You can initiate phase I clinical trials before filing your IND submission by conducting your research in Australia. Learn about the benefits and the myths for conducting your nonclinical and clinical trials in Australia by attending the next expert panel discussion! Learn more: https://www.agilexbiolabs.com/seeking-clarity-the-myths-about-nonclinical-and-clinical-trials-in-australia/

Seeking Clarity: The Myths About Nonclinical and Clinical Trials in Australia

Technology Networks

Speaking at the Vaccine Research & Development 2022 online symposium, Zoltan Kis from the University of Sheffield discussed digital design for RNA vaccine and therapeutic production.

Quality by Digital Design for RNA Vaccine and Therapeutic Production

Speaking at the Vaccine Research & Development 2022 online symposium, Nikolai Petrovsky delivered his talk on the first Australian-developed vaccine in over 40 years.

Covax-19/Spikogen: the First Australian-Developed Human Vaccine in Four Decades

Speaking at the Vaccine Research & Development 2022 online symposium, Bryce Chackerian from the University of New Mexico School of Medicine delivered his talk on the development of epitope-targeted vaccines for malaria.

Developing Epitope-Targeted Vaccines for Malaria

Speaking at the Vaccine Research & Development 2022 online symposium. Daniel Lingwood of Harvard Medical School delivered his talk on gene-encoded B cell recognition of viruses.

Gene Encoded B Cell Recognition of Viruses

Speaking at the Advances in Drug Discovery & Development 2022 online symposium, Leonardo Ferreira discussed how human regulatory T cells can protect against immune attack in type 1 diabetes.

Immunology

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.